FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365482302> ?p ?o ?g. }

• W4365482302 endingPage "3676" @default.
• W4365482302 startingPage "3666" @default.
• W4365482302 abstract "Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report here the prognostic impact of these biomarkers in patients allografted for AML/MDS. One hundred eighty-seven patients from FIGARO, a randomized trial of reduced-intensity conditioning regimens in AML/MDS, were alive and relapse-free at the first MRD time-point and provided monitoring samples for flow cytometric MRD and T-cell chimerism, requested to month+12. Twenty-nine (15.5%) patients had at least 1 MRD-positive result posttransplant. MRD-positivity was associated with reduced overall survival (OS) (hazard ratio [HR], 2.18; P = .0028) as a time-varying Cox variable and remained significant irrespective of pretransplant MRD status in multivariate analyses (P < .001). Ninety-four patients had sequential MRD with T-cell chimerism results at months+3/+6. Patients with full donor T-cell chimerism (FDTC) had an improved OS as compared with patients with mixed donor T-cell chimerism (MDTC) (adjusted HR=0.4; P = .0019). In patients with MDTC (month+3 or +6), MRD-positivity was associated with a decreased 2-year OS (34.3%) vs MRD-negativity (71.4%) (P = .001). In contrast, in the group with FDTC, MRD was infrequent and did not affect the outcome. Among patients with posttransplant MRD-positivity, decreased HLA-DR expression on blasts significantly reduced OS, supporting this as a mechanism for GVL escape. In conclusion, posttransplant MRD is an important predictor of the outcome in patients allografted for AML/MDS and is most informative when combined with T-cell chimerism results, underlining the importance of a GVL effect in AML/MDS." @default.
• W4365482302 created "2023-04-15" @default.
• W4365482302 creator A5000220772 @default.
• W4365482302 creator A5000892631 @default.
• W4365482302 creator A5002273177 @default.
• W4365482302 creator A5011143459 @default.
• W4365482302 creator A5016267427 @default.
• W4365482302 creator A5028452852 @default.
• W4365482302 creator A5030102793 @default.
• W4365482302 creator A5031479101 @default.
• W4365482302 creator A5035067892 @default.
• W4365482302 creator A5036384569 @default.
• W4365482302 creator A5048812775 @default.
• W4365482302 creator A5055406209 @default.
• W4365482302 creator A5057835568 @default.
• W4365482302 creator A5061255929 @default.
• W4365482302 creator A5063078200 @default.
• W4365482302 creator A5069954665 @default.
• W4365482302 creator A5070847211 @default.
• W4365482302 creator A5071608606 @default.
• W4365482302 creator A5081487269 @default.
• W4365482302 creator A5090325483 @default.
• W4365482302 date "2023-07-17" @default.
• W4365482302 modified "2023-10-01" @default.
• W4365482302 title "Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS" @default.
• W4365482302 cites W1575533059 @default.
• W4365482302 cites W1631320694 @default.
• W4365482302 cites W1970298901 @default.
• W4365482302 cites W1976750551 @default.
• W4365482302 cites W1994975248 @default.
• W4365482302 cites W2033971288 @default.
• W4365482302 cites W2055034746 @default.
• W4365482302 cites W2115721890 @default.
• W4365482302 cites W2118693086 @default.
• W4365482302 cites W2128185637 @default.
• W4365482302 cites W2144395887 @default.
• W4365482302 cites W2154189404 @default.
• W4365482302 cites W2290759365 @default.
• W4365482302 cites W2590030902 @default.
• W4365482302 cites W2591084969 @default.
• W4365482302 cites W2794657766 @default.
• W4365482302 cites W2896822607 @default.
• W4365482302 cites W2898648224 @default.
• W4365482302 cites W2901332394 @default.
• W4365482302 cites W2920079662 @default.
• W4365482302 cites W2925256229 @default.
• W4365482302 cites W2952113860 @default.
• W4365482302 cites W2996077324 @default.
• W4365482302 cites W2996657019 @default.
• W4365482302 cites W3115439304 @default.
• W4365482302 cites W3158625116 @default.
• W4365482302 cites W3209416216 @default.
• W4365482302 cites W4205830254 @default.
• W4365482302 cites W4214880556 @default.
• W4365482302 cites W4223908014 @default.
• W4365482302 cites W4285088636 @default.
• W4365482302 cites W4298008730 @default.
• W4365482302 cites W4310126571 @default.
• W4365482302 doi "https://doi.org/10.1182/bloodadvances.2022009493" @default.
• W4365482302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37058448" @default.
• W4365482302 hasPublicationYear "2023" @default.
• W4365482302 type Work @default.
• W4365482302 citedByCount "2" @default.
• W4365482302 countsByYear W43654823022023 @default.
• W4365482302 crossrefType "journal-article" @default.
• W4365482302 hasAuthorship W4365482302A5000220772 @default.
• W4365482302 hasAuthorship W4365482302A5000892631 @default.
• W4365482302 hasAuthorship W4365482302A5002273177 @default.
• W4365482302 hasAuthorship W4365482302A5011143459 @default.
• W4365482302 hasAuthorship W4365482302A5016267427 @default.
• W4365482302 hasAuthorship W4365482302A5028452852 @default.
• W4365482302 hasAuthorship W4365482302A5030102793 @default.
• W4365482302 hasAuthorship W4365482302A5031479101 @default.
• W4365482302 hasAuthorship W4365482302A5035067892 @default.
• W4365482302 hasAuthorship W4365482302A5036384569 @default.
• W4365482302 hasAuthorship W4365482302A5048812775 @default.
• W4365482302 hasAuthorship W4365482302A5055406209 @default.
• W4365482302 hasAuthorship W4365482302A5057835568 @default.
• W4365482302 hasAuthorship W4365482302A5061255929 @default.
• W4365482302 hasAuthorship W4365482302A5063078200 @default.
• W4365482302 hasAuthorship W4365482302A5069954665 @default.
• W4365482302 hasAuthorship W4365482302A5070847211 @default.
• W4365482302 hasAuthorship W4365482302A5071608606 @default.
• W4365482302 hasAuthorship W4365482302A5081487269 @default.
• W4365482302 hasAuthorship W4365482302A5090325483 @default.
• W4365482302 hasBestOaLocation W43654823021 @default.
• W4365482302 hasConcept C126322002 @default.
• W4365482302 hasConcept C143998085 @default.
• W4365482302 hasConcept C203014093 @default.
• W4365482302 hasConcept C207103383 @default.
• W4365482302 hasConcept C2777408962 @default.
• W4365482302 hasConcept C2778461978 @default.
• W4365482302 hasConcept C2778729363 @default.
• W4365482302 hasConcept C2779282312 @default.
• W4365482302 hasConcept C2779823535 @default.
• W4365482302 hasConcept C2911091166 @default.
• W4365482302 hasConcept C38180746 @default.
• W4365482302 hasConcept C44249647 @default.

• next